|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bevacizumab biosimilar LY01008 compared with bevacizumab(Avastin)as first-line treatment for Chinese patients with unresectable,metastatic,or recurrent non-squamous non-small-cell lung cancer:A multicenter,randomized,double-blinded,phase Ⅲ trial显示文摘Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or death.The primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and safety.This study was registered in Clinical Trials.gov(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)group.As of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)months.ORRof responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,respectively.The stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,or recurrent non-squamous NSCLC patients in the first-line setting. | Yuankai Shi Kaijian Lei Yuming Jia Bingqiang Ni Zhiyong He Minghong Bi Xicheng Wang Jianhua Shi Ming Zhou Qian Sun Guolei Wang Dongji Chen Yongqian Shu Lianke Liu Zhongliang Guo Yong Liu Junquan Yang Ke Wang Ke Xiao LinWu Tienan Yi Debin Sun Mafei Kang Tianjiang Ma Yimin Mao Jinsheng Shi Tiegang Tang Yan Wang Puyuan Xing Dongqing Lv Wangjun Liao Zhiguo Luo Bin Wang Xiaohong Wu Xiaoli Zhu Shuhua Han Qisen Guo Rongyu Liu Zhiwei Lu Jianyong Zhang Jian Fang Changlu Hu Yinghua Ji Guolong Liu Hong Lu Dedong Wu Junhong Zhang Shuyang Zhu Zheng Liu Wensheng Qiu Feng Ye Yan Yu Yanqiu Zhao Qinhong Zheng Jun Chen Zhanyu Pan Yiping Zhang Wenjuan Lian Bo Jiang Bo Qiu Guojun Zhang Hua Zhang Yanju Chen Yuan Chen Hongbing Duan Manxiang Li Shengming Liu Lijun Ma Hongming Pan Xia Yuan Xueli Yuan Yulong Zheng Emei Gao Li Zhao Shumin Wang Can Wu | 2021 | Cancer Communications2021，41，9： | 5 |
| 2 | Single-cell transcriptomic landscape of human blood cells显示文摘High throughput single-cell RNA-seq has been successfully implemented to dissect the cellular and molecular features underlying hematopoiesis.However,an elaborate and comprehensive transcriptome reference of the whole blood system is lacking.Here,we profiled the transcriptomes of 7551 human blood cells representing 32 immunophenotypic cell types,including hematopoietic stem cells,progenitors and mature blood cells derived from 21 healthy donors.With high sequencing depth and coverage,we constructed a single-cell transcriptional atlas of blood cells(ABC) on the basis of both protein-coding genes and long noncoding RNAs(lncRNAs),and showed a high consistence between them.Notably,putative lncRNAs and transcription factors regulating hematopoietic cell differentiation were identified.While common transcription factor regulatory networks were activated in neutrophils and monocytes,lymphoid cells dramatically changed their regulatory networks during differentiation.Furthermore,we showed a subset of nucleated erythrocytes actively expressing immune signals,suggesting the existence of erythroid precursors with immune functions.Finally,a web portal offering transcriptome browsing and blood cell type prediction has been established.Thus,our work provides a transcriptional map of human blood cells at single-cell resolution,thereby offering a comprehensive reference for the exploration of physiological and pathological hematopoiesis. | Xiaowei Xie Mengyao Liu Yawen Zhang Bingrui Wang Caiying Zhu Chenchen Wang Qing Li Yingying Huo Jiaojiao Guo Changlu Xu Linping Hu Aiming Pang Shihui Ma Una Wang Wenbin Cao Shulian Chen Qiuling Li Sudong Zhang Xueying Zhao Wen Zhou Hongbo Luo Guoguang Zheng Erlie Jiang Sizhou Feng Lixiang Chen Lihong Shi Hui Cheng Sha Hao Ping Zhu Tao Cheng | 2021 | National Science Review2021，8，3： | 3 |
| 3 | Prevalence of Dyslipidemia and Associated Factors Among the Hypertensive Rural Chinese Population显示文摘 | Xingang Zhang Zhaoqing Sun Liqiang Zheng Jue Li Shuangshuang Liu Changlu Xu Jiajin Li Fenfen Zhao Dayi Hu Yingxian Sun | 2007 | Archives of Medical Research2007，，4： | 1 |
| 4 | Pulse Pressure and Mean Arterial Pressure in Relation to Ischemic Stroke Among Patients With Uncontrolled Hypertension in Rural Areas of China显示文摘 | Liqiang Zheng Zhaoqing Sun Jue Li Rui Zhang Xingang Zhang Shuangshuang Liu Jiajin Li Changlu Xu Dayi Hu Yingxian Sun | 2008 | Stroke2008，，7： | 1 |
| 5 | Pulse Pressure and Mean Arterial Pressure in Relation to Ischemic Stroke Among Patients With Uncontrolled Hypertension in Rural Areas of China显示文摘 | Liqiang Zheng Zhaoqing Sun Jue Li Rui Zhang Xingang Zhang Shuangshuang Liu Jiajin Li Changlu Xu Dayi Hu Yingxian Sun | 2008 | Stroke2008，，7： | 1 |
| 6 | Intrinsic emission and tunable phosphorescence of perfluorosulfonate ionomers with evolved ionic clusters显示文摘Intrinsic emission from unorthodox luminogens without traditional conjugated building blocks is drawing increasing attention.However,the emission mechanism is still controversial.Herein,we demonstrate the intriguing emission from perfluorosulfonate ionomers(PFSIs),which can be explained by the clustering triggered emission(CTE)mechanism.Despite being free of any conventional chromophores,PFSIs exhibit bright emission and multi-color phosphorescence(77 K)in concentrated solutions,powders and membranes with obvious aggregation-induced emission(AIE)characteristics.Clustered sulfonic acids are responsible for the light emission,and their connection and evolution are deeply explored via X-ray diffraction(XRD)and small angel X-ray scattering(SAXS),in which the electron overlap determined by the clustered status results in the extended conjugation and simultaneously rigidified conformations.These results demonstrate that it is feasible to use fluorescence analysis to explore the ionic cluster structure and evolution of PFSI,and it can be applied in the pure organic luminescent field as well. | Qing Zhou Jia Cui Tianjia Yang Changlu Hu Zihao Zhong Zhenhua Sun Yongyang Gong Supeng Pei Yongming Zhang | 2020 | Science China Chemistry2020，63，6： | 0 |
| 7 | The S-RHT(R) Technology for Residue Hydrotreating显示文摘The S-RHT technology is developed by FRIPP for residue hydrotreating in the fixed bed in order to process the high sulfur crude and increase the yield of light distillates. The technology can be used for treating various kinds of atmospheric residues (AR) or vacuum residues (VR) with a total metal content less than 150 ppm under the operating conditions of a temperature ranging from 360-410℃, a hydrogen partial pressure of 14-15 MPa, a LHSV of 0.20-0.30h-1 and a hydrogen to oil ratio of 700-1000. A certain amount of light products can be obtained and the hydrotreated atmospheric residue can fully meet the needs for the feedstock to RFCC or a blending feedstock to FCC. Based on the S-RHT technology, a 2 Mt/a residue hydrotreating unit has been constructed and successfully started up at Maoming Petrochemical Company by the end of 1999. | Han Chongren Wang Gang Hu Changlu | 2001 | China Petroleum Processing & Petrochemical Technology2001，3，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员